Literature DB >> 34027035

FOXA1 mutations influence the therapeutic response of breast cancer by altering chromatin state.

Amaia Arruabarrena-Aristorena1, Eneda Toska2,3.   

Abstract

Forkhead box protein A1 (FOXA1) is a pioneer transcription factor that contributes to chromatin opening to allow binding of estrogen receptor (ER) in ER+ breast cancer. Mutations in FOXA1 are recurrent in breast cancer but the functional consequences of these mutations remain unknown. We identified that FOXA1 mutations are associated with worse outcomes to endocrine therapy by inducing alternative chromatin profiles and gene activity in breast cancer.
© 2021 Taylor & Francis Group, LLC.

Entities:  

Keywords:  Breast cancer; FOXA1 mutations; chromatin regulation; endocrine therapy; estrogen receptor

Year:  2021        PMID： 34027035      PMCID： PMC8128199          DOI： 10.1080/23723556.2021.1891831

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

Review 1.  Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state.

Authors:  Kelly A Green; Jason S Carroll
Journal:  Nat Rev Cancer       Date:  2007-09       Impact factor: 60.716

2.  The Pioneer Transcription Factor FoxA Maintains an Accessible Nucleosome Configuration at Enhancers for Tissue-Specific Gene Activation.

Authors:  Makiko Iwafuchi-Doi; Greg Donahue; Akshay Kakumanu; Jason A Watts; Shaun Mahony; B Franklin Pugh; Dolim Lee; Klaus H Kaestner; Kenneth S Zaret
Journal:  Mol Cell       Date:  2016-04-07       Impact factor: 17.970

3.  Binding of the winged-helix transcription factor HNF3 to a linker histone site on the nucleosome.

Authors:  L A Cirillo; C E McPherson; P Bossard; K Stevens; S Cherian; E Y Shim; K L Clark; S K Burley; K S Zaret
Journal:  EMBO J       Date:  1998-01-02       Impact factor: 11.598

4.  Steroid Receptors Reprogram FoxA1 Occupancy through Dynamic Chromatin Transitions.

Authors:  Erin E Swinstead; Tina B Miranda; Ville Paakinaho; Songjoon Baek; Ido Goldstein; Mary Hawkins; Tatiana S Karpova; David Ball; Davide Mazza; Luke D Lavis; Jonathan B Grimm; Tatsuya Morisaki; Lars Grøntved; Diego M Presman; Gordon L Hager
Journal:  Cell       Date:  2016-04-07       Impact factor: 41.582

5.  FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.

Authors:  Amaia Arruabarrena-Aristorena; Jesper L V Maag; Srushti Kittane; Yanyan Cai; Wouter R Karthaus; Erik Ladewig; Jane Park; Srinivasaraghavan Kannan; Lorenzo Ferrando; Emiliano Cocco; Sik Y Ho; Daisylyn S Tan; Mirna Sallaku; Fan Wu; Barbara Acevedo; Pier Selenica; Dara S Ross; Matthew Witkin; Charles L Sawyers; Jorge S Reis-Filho; Chandra S Verma; Ralf Jauch; Richard Koche; José Baselga; Pedram Razavi; Eneda Toska; Maurizio Scaltriti
Journal:  Cancer Cell       Date:  2020-09-03       Impact factor: 31.743

6.  PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.

Authors:  Eneda Toska; Hatice U Osmanbeyoglu; Pau Castel; Carmen Chan; Ronald C Hendrickson; Moshe Elkabets; Maura N Dickler; Maurizio Scaltriti; Christina S Leslie; Scott A Armstrong; José Baselga
Journal:  Science       Date:  2017-03-24       Impact factor: 47.728

7.  The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.

Authors:  Pedram Razavi; Matthew T Chang; Guotai Xu; Chaitanya Bandlamudi; Dara S Ross; Neil Vasan; Yanyan Cai; Craig M Bielski; Mark T A Donoghue; Philip Jonsson; Alexander Penson; Ronglai Shen; Fresia Pareja; Ritika Kundra; Sumit Middha; Michael L Cheng; Ahmet Zehir; Cyriac Kandoth; Ruchi Patel; Kety Huberman; Lillian M Smyth; Komal Jhaveri; Shanu Modi; Tiffany A Traina; Chau Dang; Wen Zhang; Britta Weigelt; Bob T Li; Marc Ladanyi; David M Hyman; Nikolaus Schultz; Mark E Robson; Clifford Hudis; Edi Brogi; Agnes Viale; Larry Norton; Maura N Dickler; Michael F Berger; Christine A Iacobuzio-Donahue; Sarat Chandarlapaty; Maurizio Scaltriti; Jorge S Reis-Filho; David B Solit; Barry S Taylor; José Baselga
Journal:  Cancer Cell       Date:  2018-09-10       Impact factor: 31.743

8.  FOXA1 is a key determinant of estrogen receptor function and endocrine response.

Authors:  Antoni Hurtado; Kelly A Holmes; Caryn S Ross-Innes; Dominic Schmidt; Jason S Carroll
Journal:  Nat Genet       Date:  2010-12-12       Impact factor: 38.330

9.  Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.

Authors:  Abhijit Parolia; Marcin Cieslik; Shih-Chun Chu; Lanbo Xiao; Takahiro Ouchi; Yuping Zhang; Xiaoju Wang; Pankaj Vats; Xuhong Cao; Sethuramasundaram Pitchiaya; Fengyun Su; Rui Wang; Felix Y Feng; Yi-Mi Wu; Robert J Lonigro; Dan R Robinson; Arul M Chinnaiyan
Journal:  Nature       Date:  2019-06-26       Impact factor: 49.962

10.  FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.

Authors:  Elizabeth J Adams; Wouter R Karthaus; Elizabeth Hoover; Deli Liu; Antoine Gruet; Zeda Zhang; Hyunwoo Cho; Rose DiLoreto; Sagar Chhangawala; Yang Liu; Philip A Watson; Elai Davicioni; Andrea Sboner; Christopher E Barbieri; Rohit Bose; Christina S Leslie; Charles L Sawyers
Journal:  Nature       Date:  2019-06-26       Impact factor: 49.962
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.